CMAB Biopharma (Suzhou) Inc., a dedicated biologics contract manufacturing and development organization (CDMO), has appointed Maggie Chen as chief financial officer. Chen will lay a solid foundation for the long-term development of CDMO business and commences a new milestone for CMAB.
 
Experience
 
Chen has nearly 20 years of experience in listing, merger and acquisition, group comprehensive financial management and capital operation. In her career, she has served several pharmaceutical and biopharmaceutical group companies, and has extensive experience in financial and capital management in the pharmaceutical sector.
 
“We are very pleased to welcome Ms. Maggie Chen to CMAB.” Dr. Yongzhong Wang, CEO of CMAB, said, “Ms. Maggie Chen has extensive financial experience in the pharmaceutical field and outstanding professional ability in capital operation. CMAB is in the period of rapid and high-quality development. At this important moment, Ms. Maggie Chen’s join will further boost the vigorous development of the business of CMAB.”
 
“I am very happy to be a member of CMAB,” commented Chen. “CMAB is a rare CDMO company in the field of biopharmaceutical industry. It has a complete and advanced technology platform, and its core team has wide experience in running the business globally and the dual IND filings in both China and the United States. Its pure-play CDMO business model and the value concept of make the clients successful at the fastest speed are the perfect match for the needs of innovative drug companies in the early stages, which makes me feel excited. I look forward to working with Dr. Yongzhong Wang and all my colleagues to promote and achieve the company’s strategic objectives.”
 
Before joining CMAB, Chen served as vice president and CFO of Fosun Pharma Group, comprehensively led the financial management of the group, and promoted the upgrading of the financial system of both the group and more than 10 subsidiaries, and was responsible for the group’s capitalization projects and external financing.
 
Before joining Fosun Pharma Group, she served as CFO of Porton Pharma Solutions Ltd., responsible for financial audit and IPO preparation, realizing the company’s successful listing in China Growth Enterprise Market. During this period, she managed the financial team of subordinate subsidiaries, established the group’s financial management system, promoted the business and strategy landing of Porton, organized multiple M&A projects, and completed BPM projects, cost management improvement projects and 400 million votes issuance.
 
Chen holds a Master’s Degree from Southwest University of Finance and Economics and an EMBA from China Europe International Business School.